Thursday, Organon & Co (NYSE:OGN) reported an 8% Y/Y increase in the fourth quarter of 2023, reaching around $1.6 billion, beating the consensus of $1.55 billion.
Women’s Health revenue increased by 7% as reported and 8% ex-FX, driven by strong growth in fertility products, particularly Follistim AQ.
Follistim grew 63% ex-FX due to increased demand in the U.S. that was largely tied to onboarding a new customer, and volume recovery in China …
Leave a Reply